Committee tables LD 18‑47 after wide-ranging debate on testing, 'high‑potency' definition and packaging
Loading...
Summary
The committee paused consideration of LD 18‑47 (testing and packaging for medical and adult‑use cannabis) and asked the sponsor and stakeholders to draft a consensus amendment after contested debate over whether to define 'high potency' in the medical program as >10 mg THC per serving and require blister packaging and a special symbol.
The Joint Standing Committee on Veterans and Legal Affairs tabled LD 18‑47 after members and stakeholders debated mandatory testing frameworks and a newly proposed definition and packaging rules for 'high‑potency' medical cannabis products.
Analyst Rachel Olsen walked the committee through a memo explaining the different statutory testing frameworks for Maine's medical program and adult‑use program. Olsen said the adult‑use system has mandatory batch contaminant testing, closed‑loop inventory tracking and explicit authority for audit testing and samples; by contrast, she explained, statutory changes over time had removed or altered language authorizing specific testing and annual spot checks in the medical program, leaving ambiguity about enforcement of older 2018 rules.
Representative Annie Graham, sponsor of the amendment, said she revised the bill after stakeholder meetings to remove a medical potency cap while introducing a 'high potency' definition that would trigger extra safeguards. "This new amendment does 4 things," Graham said. She listed: (1) a definition of high‑potency (more than 10 milligrams THC per serving) and labeling requirements; (2) blister packaging for high‑potency edibles (with some exceptions for tinctures and liquids); (3) reporting to the Office of Cannabis Policy of high‑potency products; and (4) patient education materials the office would develop.
Industry witnesses and caregivers pushed back on the 10‑mg threshold. Caregiver David Stevenson, who said he has served patients since 2011 and operates AU retail stores, told the committee that he does not regard 11 mg as 'high potency' and suggested a far higher threshold (he cited ~100 mg). He also said changing labeling and packaging would be costly for small operators: "It would be a cost burden for sure," he said.
Public‑health witnesses, including Becca Bolos of the Maine Public Health Association, cited peer‑reviewed research and dose‑response evidence linking higher THC exposure to elevated risk of psychosis among young people and argued for labeling and packaging steps that reduce accidental pediatric ingestions. Bolos said the policy intent was to reduce youth exposures and accidental ingestions and to make products more transparent for patients.
Committee members sought epidemiological details: several asked whether Poison Control and HHS data could distinguish the origin of pediatric exposures (adult‑use, medical, hemp‑derived products). Analysts and OCP committed to follow up; the committee also requested OCP and public‑health materials and studies cited by witnesses.
After caucus and stakeholder bargaining, the chair instructed the sponsor and industry (with analyst assistance) to draft a consensus amendment and circulate it before the committee reconvenes. LD 18‑47 was tabled to allow that process; the chair set a follow‑up schedule so members and stakeholders will have time to review revised language before a final meeting.
